Somnus Therapeutics

Bedminster, United States Founded: 2007 • Age: 19 yrs
Controlled-release sleep maintenance therapeutics are developed by the company.

About Somnus Therapeutics

Somnus Therapeutics is a company based in Bedminster (United States) founded in 2007.. Somnus Therapeutics has raised $15 million across 1 funding round. Somnus Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Bedminster, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $15 M (USD)

    in 1 rounds

  • Latest Funding Round
    $15 M (USD), Series A

    Feb 11, 2010

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Somnus Therapeutics

Somnus Therapeutics has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series A round of $15 million completed in February 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $15.0M
  • First Round

    (11 Feb 2010)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2010 Amount Series A - Somnus Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Somnus Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Somnus Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Somnus Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Somnus Therapeutics

Somnus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
CRISPR-engineered cell and gene therapies are developed for research applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Somnus Therapeutics

Frequently Asked Questions about Somnus Therapeutics

When was Somnus Therapeutics founded?

Somnus Therapeutics was founded in 2007 and raised its 1st funding round 3 years after it was founded.

Where is Somnus Therapeutics located?

Somnus Therapeutics is headquartered in Bedminster, United States. It is registered at Bedminster, New Jersey, United States.

Is Somnus Therapeutics a funded company?

Somnus Therapeutics is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series A of $15M, raised on Feb 11, 2010.

What does Somnus Therapeutics do?

Somnus Therapeutics, a private specialty pharmaceutical company, has developed a controlled-release sleep-maintenance therapeutic drug. In June 2007, Somnus entered into an exclusive agreement with SkyePharma for the worldwide development and commercialization of its sleep therapeutic, SKP-1041. Under the agreement, SkyePharma will formulate and manufacture SKP-1041, a new controlled-release formulation of a non-benzodiazepine hypnotic agent using SkyePharmas GeoclockTM technology.

Who are the top competitors of Somnus Therapeutics?

Somnus Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available